Tritace 2.5 Mg 28Tab

-Chronic hypertension: Oral: Initial: 2.5 mg once daily; evaluate response after ~2 to 4 weeks and titrate dose (eg, increase the daily dose by doubling) as needed, up to 20 mg/day in 1 or 2 divided doses; if additional blood pressure control is needed, consider combination therapy. Patients with severe asymptomatic hypertension and no signs of acute end organ damage should be evaluated for medication titration within 1 week. -Acute coronary syndrome: 1-Non–ST-elevation acute coronary syndrome: Oral: Initial: 2.5 mg once daily; titrate slowly based on tolerability and response up to 20 mg/day in 1 or 2 divided doses. 2-ST-elevation acute coronary syndrome: Oral: Initial: 2.5 mg once daily initiated within 24 hours of presentation; titrate slowly based on tolerability and response up to 20 mg/day in 1 or 2 divided doses. -Heart failure with reduced ejection fraction: Oral: Initial: 1.25 mg once daily; as tolerated, may increase dose (eg, double) every ≥2 weeks to a target dose of 10 mg once daily. -Proteinuric chronic kidney disease: Oral: Initial: 1.25 to 2.5 mg once daily depending on blood pressure; titrate slowly based on tolerability and response up to 10 mg/day in 1 or 2 divided doses. -Reduction in risk of myocardial infarction, stroke, and death from cardiovascular causes: Oral: Initial: 2.5 mg once daily for 1 week, then 5 mg once daily for the next 3 weeks, then increase as tolerated to maintenance dose of 10 mg/day in 1 or 2 divided doses.